Observational Cohort of COVID-19 Patients in Hubei Province

计划入组 68,000 人 · 首次发布于 2022 年 11 月 14 日

Effectiveness of Pharmacotherapy Follow-up Care in Outpatients With Type 2 Diabetes Mellitus

计划入组 60 人 · 首次发布于 2017 年 6 月 22 日

Placebo Controlled Study of Sublingual Salvinorin A

计划入组 8 人 · 首次发布于 2010 年 6 月 24 日

Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 antigen (propiolactone inactivated)

NMUR2 agonists (Takeda Pharmaceutical)

PL-1 (Protelight Pharmaceutical)

HUBEI GUANGJI PHARMACEUTICAL CO., LTD.

Hubei Biocause Heilen Pharmaceutical Co., Ltd.

China

Hubei Hongyuan Pharmaceutical Technology Co.,Ltd.

Kazakhstan Registers Promomed's Tirzetta as First Officially Available Tirzepatide Drug in the Country

HanAll, Daewoong, and NurrOn Announce Positive Phase 1 Results for Parkinson's Disease Therapy HL192 (ATH-399A)

NIH Initiates Clinical Trial of Remdesivir for COVID-19 in the U.S.